Prosthetic valve thrombosis (PVT) is an increasingly recognized complication of bioprosthetic valve replacement, often resulting in abnormal hemodynamic, endothelial, and hemostatic conditions. Bioprosthetic PVT may lead to significant hemodynamic and clinical effects. In hemodynamically stable patients, first-line treatment for bioprosthetic PVT is systemic anticoagulation. However, concomitant cardiovascular pathology may lead to additional clinical sequalae that requires acute therapeutic interventions. We describe two cases in which bioprosthetic PVT leads to hemodynamically significant intracardiac shunting through pre-existing patent foramen ovales requiring percutaneous closure with a Cribriform AMPLATZER occluder device. We also review the treatment for bioprosthetic PVT and discuss important clinical and hemodynamic considerations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ccd.27217 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Simplified balloon-BASILICA: A different perspective.
Catheter Cardiovasc Interv
August 2024
Department of Cardiac Surgery, Valve Center-IRCCS San Raffaele Scientific Institute, Milan, Italy.
Article Synopsis
- The management of patients with aortic stenosis is a hot topic, especially with the rise of transcatheter aortic valve replacement (TAVR) procedures in younger, lower-risk individuals.
- The BASILICA technique is designed to prevent coronary obstruction during valve-in-valve procedures but is known to be complex and time-consuming.
- A new, simplified version of the BASILICA technique using an Armada Balloon for leaflet laceration is being introduced as a more efficient alternative.
Comprehensive collection of COVID-19 related prosthetic valve failure: a systematic review.
J Thromb Thrombolysis
April 2023
Smidt Heart Institute, Cedars-Sinai Hospital, 8501 Wilshire Blvd Suite 200, Beverly Hills, Los Angeles, CA, USA.
Since the beginning of the SARS-CoV-2 (COVID-19) pandemic, correlation of venous thromboembolism (VTE) and COVID-19 infection has been well established. Increased inflammatory response in the setting of COVID-19 infection is associated with VTE and hypercoagulability. Venous and arterial thrombotic events in COVID-19 infection have been well documented; however, few cases have been reported involving cardiac valve prostheses.
View Article and Find Full Text PDFContact pathway in surgical and transcatheter aortic valve replacement.
Front Cardiovasc Med
July 2022
Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, Universidad de Murcia, IMIB-Arrixaca, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Murcia, Spain.
Background: Aortic valve replacement is the gold standard treatment for severe symptomatic aortic stenosis, but thrombosis of bioprosthetic valves (PVT) remains a concern.
Objective: To analyze the factors involved in the contact pathway during aortic valve replacement and to assess their impact on the development of thromboembolic complications.
Methods: The study was conducted in 232 consecutive patients who underwent: transcatheter aortic valve replacement (TAVR, = 155), and surgical valve replacement (SAVR, = 77) (MUVITAVI project).
Transcatheter Tricuspid Valve-in-Valve Implantation With a Novel Balloon Expandable Myval THV.
Ann Thorac Surg
December 2021
Department of Cardiology, Medicana International Ankara Hospital, Ankara, Turkey.
The transcatheter tricuspid valve-in-valve implantation has not yet been clarified, and several case series have documented results in patients with tricuspid bioprosthetic valve degeneration who underwent transcatheter implantation of Edwards SAPIEN XT and SAPIEN 3 (Edwards Lifesciences, Irvine, CA) and Medtronic (Minneapolis, MN) valves. Here, we present the case of a patient with severe bioprosthetic tricuspid valve stenosis who was successfully treated with the transfemoral route through the 29-mm novel balloon expandable Myval transcatheter heart valve (Meril Life Sciences Pvt Ltd, Vapi, Gujarat, India) system.
View Article and Find Full Text PDFMyval transcatheter heart valve system in the treatment of severe symptomatic aortic stenosis.
Future Cardiol
January 2021
Department of Cardiology, Apollo Hospital Enterprise Limited, Chennai, Tamil Nadu 600006, India.
The transcatheter aortic valve replacement (TAVR) is an established treatment for patients with severe symptomatic aortic stenosis (AS) at prohibitive risk for surgery. It is an alternative treatment to surgical aortic valve replacement in patients with AS at intermediate- and high-surgical risk. Although regulatory authorities extend the indications of TAVR to treat patients at low-surgical risk, the limitations of earlier-generation transcatheter heart valve (THV) systems accelerate the development of improved newer generation of THV systems.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!